AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17708609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum IL-18 levels (< 10(5) pg/mL)
Number of subjects: 70
Study 17708609 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-18 levels
Number of subjects: 70
Study 15100587 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral analgesics (ketorolac, diclofenac potassium, bromfenac, tramadol, hydrocodone/ibuprofen fixed combination, celecoxib, rofecoxib, tramadol/acetaminophen, valdecoxib)
Number of subjects: 9
Study 15100587 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral analgesics (5 of the 9 drugs)
Number of subjects: 9
Study 15100587 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral analgesics
Number of subjects: 9
Study 11535953 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol administered into the posterior vaginal fornix (group M)
Number of subjects: 56
Study 11535953 — intervention group
Group type: COMPARATOR
Intervention: Natural prostaglandin E(2) (group P)
Number of subjects: 56
Study 8986703 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic serum substitute
Number of subjects: 45
Study 8986703 — intervention group
Group type: COMPARATOR
Intervention: Fetal cord serum (FCS)
Number of subjects: 45
Study 8098277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 55
Study 8098277 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 55
Study 8098277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 55
Study 8098277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3556381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of meptazinol
Number of subjects: 7
Study 3556381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of meptazinol
Number of subjects: 7
Study 3556381 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients
Number of subjects: 7
Study 3556381 — intervention group
Group type: COMPARATOR
Intervention: Young volunteers (ages 20-40 years)
Number of subjects: 7
Study 31309333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily for 100 days
Number of subjects: 89
Study 31309333 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 100 days
Number of subjects: 89
Study 28652529 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib 130 mg once daily for 12 weeks
Number of subjects: 54
Study 28652529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26039494 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (20 min session with an animal-assisted therapy dog after surgery)
Number of subjects: 40
Study 26039494 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Number of subjects: 40
Study 26039494 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 40
Study 23550779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral injection of Biolon (sodium‐hyaluronate 1%)
Number of subjects: 60
Study 23550779 — intervention group
Group type: COMPARATOR
Intervention: No use of OVD (control group)
Number of subjects: 60
Study 21747241 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide 160/12.5 mg combination therapy
Number of subjects: 108
Study 21747241 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg monotherapy
Number of subjects: 108
Study 21747241 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg monotherapy
Number of subjects: 108
Study 18794161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of 400 microg misoprostol every 3 h up to five doses
Number of subjects: 681
Study 18794161 — intervention group
Group type: COMPARATOR
Intervention: Sublingual administration of 400 microg misoprostol every 3 h up to five doses
Number of subjects: 681
Study 18794161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of 400 microg misoprostol
Number of subjects: 681
Study 18794161 — intervention group
Group type: COMPARATOR
Intervention: Sublingual administration of 400 microg misoprostol
Number of subjects: 681
Study 18794161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration
Number of subjects: 681
Study 18794161 — intervention group
Group type: COMPARATOR
Intervention: Sublingual administration
Number of subjects: 681
Study 18794161 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 681
Study 17101852 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/d)
Number of subjects: 114
Study 17101852 — intervention group
Group type: COMPARATOR
Intervention: Control (no enalapril)
Number of subjects: 114
Study 15626947 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of DTPa-HBV-IPV/Hib and meningococcal C conjugate vaccines during the same visit
Number of subjects: 452
Study 15626947 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of DTPa-HBV-IPV/Hib vaccine and meningococcal C conjugate vaccine
Number of subjects: 452
Study 11452243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg single oral dose in poor metabolizers
Number of subjects: 12
Study 11452243 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 100 mg single oral dose in extensive metabolizers
Number of subjects: 12
Study 11452243 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylsertraline in poor metabolizers
Number of subjects: 12
Study 11452243 — intervention group
Group type: COMPARATOR
Intervention: Desmethylsertraline in extensive metabolizers
Number of subjects: 12
Study 9506548 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (selegiline)
Number of subjects: 800
Study 9506548 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol
Number of subjects: 800
Study 9506548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments
Number of subjects: 800
Study 9506548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 7924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte sodium-lithium (Na-Li) countertransport in IDDM group
Number of subjects: 84
Study 7924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte sodium-lithium (Na-Li) countertransport in IDDM subjects with MA
Number of subjects: 84
Study 7924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte sodium-lithium (Na-Li) countertransport in IDDM subjects without MA
Number of subjects: 84
Study 7924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HbA1c and Na-Li countertransport in IDDM group
Number of subjects: 84
Study 7924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP in IDDM group with MA
Number of subjects: 84
Study 7924781 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte sodium-lithium (Na-Li) countertransport in siblings
Number of subjects: 84
Study 2899413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 2
Study 2899413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 2
Study 31961489 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention (2-step intervention: 18-week diet and exercise program followed by 4 treatment subgroups)
Number of subjects: 171
Study 31961489 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 171
Study 31961489 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention
Number of subjects: 171
Study 30032274 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT group
Number of subjects: 73
Study 30032274 — intervention group
Group type: COMPARATOR
Intervention: non-ADT group
Number of subjects: 73
Study 27216492 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin DR 500 mg twice-daily
Number of subjects: 26
Study 27216492 — intervention group
Group type: COMPARATOR
Intervention: Metformin IR 1000 mg twice-daily
Number of subjects: 26
Study 27216492 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin DR 1000 mg once-daily in the morning
Number of subjects: 26
Study 27216492 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin DR 1000 mg once-daily in the evening
Number of subjects: 26
Study 25610796 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cord blood transfusions in conjunction with physical and occupational therapies
Number of subjects: 17
Study 25610796 — intervention group
Group type: COMPARATOR
Intervention: Autologous cord blood transfusions
Number of subjects: 17
Study 23681955 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 40
Study 23681955 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (up to 100 mg/day)
Number of subjects: 40
Study 20606024 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP with IVTA (30 eyes)
Number of subjects: 76
Study 20606024 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP with IVB (31 eyes)
Number of subjects: 76
Study 20606024 — intervention group
Group type: COMPARATOR
Intervention: PRP only (30 eyes)
Number of subjects: 76
Study 20606024 — intervention group
Group type: EXPERIMENTAL
Intervention: IVTA group (30 eyes)
Number of subjects: 76
Study 17944983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled adenosine A2A receptor agonist (GW328267X), 25 microg
Number of subjects: 15
Study 17944983 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate, 250 microg
Number of subjects: 15
Study 16798861 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation plus non-fluoride dentifrice
Number of subjects: 17
Study 16798861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice
Number of subjects: 17
Study 16798861 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation plus fluoride dentifrice
Number of subjects: 17
Study 16798861 — intervention group
Group type: COMPARATOR
Intervention: non-fluoride dentifrice
Number of subjects: 17
Study 12428638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 61
Study 12428638 — intervention group
Group type: COMPARATOR
Intervention: Propofol target‐controlled infusion at 6 microg.ml(‐1)
Number of subjects: 61
Study 9670176 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 9670176 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 0
Study 7927547 — intervention group
Group type: EXPERIMENTAL
Intervention: C. trachomatis antigen detection
Number of subjects: 365
Study 7927547 — intervention group
Group type: EXPERIMENTAL
Intervention: T. gondii (IgM) antibodies detection
Number of subjects: 365
Study 7927547 — intervention group
Group type: EXPERIMENTAL
Intervention: M. hominis (IgG) antibodies detection
Number of subjects: 365
Study 7927547 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 women with normal infants)
Number of subjects: 365
Study 2690235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine 30 mg b.i.d. p.o.
Number of subjects: 237
Study 2690235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 1096695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive method (deriving rules from pulmonary function data and correct diagnoses)
Number of subjects: 0
Study 1096695 — intervention group
Group type: COMPARATOR
Intervention: Deductive method (using a computer-assisted instructional program)
Number of subjects: 0
Study 31855922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration without prior lavage (Group I)
Number of subjects: 286
Study 31855922 — intervention group
Group type: COMPARATOR
Intervention: Aspiration after lavage with 500 mL physiological saline (Group II)
Number of subjects: 286
Study 31293193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) Oxford UKA
Number of subjects: 62
Study 31293193 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) Sigma UKA
Number of subjects: 62
Study 31293193 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MB and FB)
Number of subjects: 62
Study 28677879 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 530
Study 28677879 — intervention group
Group type: COMPARATOR
Intervention: Appendicectomy
Number of subjects: 530
Study 23911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Recommendation Tracking Form (MRTF)
Number of subjects: 0
Study 23911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous CGI-BP depression score
Number of subjects: 0
Study 23911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous CGI-BP overall severity score
Number of subjects: 0
Study 23911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous Montgomery Asberg Depression Rating Scale (MADRS) score
Number of subjects: 0
Study 23911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous Young Mania Rating Scale (YMRS) score
Number of subjects: 0
Study 23911057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer NCAs
Number of subjects: 0
Study 21293307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low graduated compression stockings (12-15 mm Hg)
Number of subjects: 12
Study 21293307 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium graduated compression stockings (18-21 mm Hg)
Number of subjects: 12
Study 21293307 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mm Hg)
Number of subjects: 12
Study 21293307 — intervention group
Group type: EXPERIMENTAL
Intervention: High graduated compression stockings (23-32 mm Hg)
Number of subjects: 12
Study 19656211 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 1400
Study 19656211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 17429085 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT-Hib-IPV (Group A)
Number of subjects: 166
Study 17429085 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT-Hib-IPV (Group C)
Number of subjects: 166
Study 17429085 — intervention group
Group type: COMPARATOR
Intervention: DPT-Hib (Group B)
Number of subjects: 166
Study 17429085 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT-Hib-IPV (Group A, C)
Number of subjects: 166
Study 15587100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrinsing conditioner (NRC) with Prime & Bond NT/PMRC sealants
Number of subjects: 141
Study 15587100 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid-conditioned Prime & Bond NT/PMRC sealants
Number of subjects: 141
Study 15587100 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid-conditioned Delton sealants
Number of subjects: 141
Study 11463764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 38
Study 11463764 — intervention group
Group type: COMPARATOR
Intervention: Ordinary sodium diet
Number of subjects: 38
Study 9722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI) with seven preseasonal injections of tree-pollen allergens (ALK7 Frühblühermischung)
Number of subjects: 111
Study 9722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI)
Number of subjects: 111
Study 9722222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 8276370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (20 mg initial dose, increased to 60 mg/day if no response)
Number of subjects: 40
Study 8276370 — intervention group
Group type: COMPARATOR
Intervention: Potassium canrenoate (150 mg initial dose, increased to 500 mg/day if no response)
Number of subjects: 40
Study 8276370 — intervention group
Group type: COMPARATOR
Intervention: Potassium canrenoate (for nonresponders to amiloride)
Number of subjects: 40
Study 8276370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (for nonresponders to potassium canrenoate)
Number of subjects: 40
Study 8276370 — intervention group
Group type: COMPARATOR
Intervention: Comparison of responders and nonresponders to potassium canrenoate
Number of subjects: 40
Study 2346202 — intervention group
Group type: COMPARATOR
Intervention: Tono-Pen
Number of subjects: 130
Study 2346202 — intervention group
Group type: COMPARATOR
Intervention: Pulsair
Number of subjects: 130
Study 2346202 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Number of subjects: 130
Study 1203840 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 120-hours infusion of 5-fluorouracil
Number of subjects: 70
Study 1203840 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus injection of 5-fluorouracil daily for 5 days
Number of subjects: 70
Study 31823527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg rasagiline tablet (single dose)
Number of subjects: 30
Study 31823527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg rasagiline transdermal patch (48-hour patch-on period)
Number of subjects: 30
Study 31823527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg rasagiline transdermal patch (48-hour patch-on period)
Number of subjects: 30
Study 31823527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg rasagiline tablet (repeated doses for 7 days)
Number of subjects: 30
Study 31823527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg rasagiline transdermal patch (repeated doses every 72 hours for 5 time periods)
Number of subjects: 30
Study 30715568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tile AO classification
Number of subjects: 154
Study 30715568 — intervention group
Group type: EXPERIMENTAL
Intervention: Young and Burgess classification
Number of subjects: 154
Study 30715568 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP classification
Number of subjects: 154
Study 28436727 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg)
Number of subjects: 2004
Study 28436727 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill-based treatment
Number of subjects: 2004
Study 28436727 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2004
Study 25758280 — intervention group
Group type: EXPERIMENTAL
Intervention: NOV FFR technique
Number of subjects: 56
Study 25758280 — intervention group
Group type: COMPARATOR
Intervention: CON FFR technique
Number of subjects: 56
Study 23526462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (IL) infusion
Number of subjects: 46
Study 23526462 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 46
Study 21470450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive hand hygiene campaign (washing hands twice each day and health messages through entertainment activities)
Number of subjects: 60
Study 19309189 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent, classroom-based intervention (Chicago School Readiness Project model)
Number of subjects: 35
Study 19309189 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 16857049 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP) consisting of six weekly sessions led by a CHF nurse specialist and a CHF patient.
Number of subjects: 318
Study 16857049 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 318
Study 16627035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cautery
Number of subjects: 118
Study 16627035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hulka clip
Number of subjects: 118
Study 16627035 — intervention group
Group type: COMPARATOR
Intervention: Control (Barrier contraception or abstinence)
Number of subjects: 118
Study 16627035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cautery and Hulka clip
Number of subjects: 118
Study 14713182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 108
Study 14713182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 10366121 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education (group E)
Number of subjects: 211
Study 10366121 — intervention group
Group type: COMPARATOR
Intervention: Attention control (group AC)
Number of subjects: 211
Study 7572943 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvin insulin sensitivity measure (calculated from FSIGT)
Number of subjects: 55
Study 7572943 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal model analysis (MINMOD SI(22))
Number of subjects: 55
Study 2178497 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/day triamcinolone acetonide aerosol
Number of subjects: 205
Study 2178497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 154301 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 12
Study 154301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30799495 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Motivate 1.0
Number of subjects: 38
Study 30799495 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Motivate 2.0
Number of subjects: 38
Study 30615666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 69
Study 30615666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 69
Study 30615666 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 69
Study 30615666 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 27802114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers with a quit goal)
Number of subjects: 200
Study 27802114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers)
Number of subjects: 200
Study 25770824 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppm toluene exposure
Number of subjects: 33
Study 25770824 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to toluene)
Number of subjects: 33
Study 23538154 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial catheterisation (TR, n=20)
Number of subjects: 40
Study 23538154 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral catheterisation (TF, n=20)
Number of subjects: 40